The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients
Background. We aimed to investigate the distributive characteristics of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms and their influence on metformin efficacy in Chinese T2DM patients. Methods. The distributions of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms were determined in 267 T...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2016/4350712 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550553346899968 |
|---|---|
| author | Di Xiao Yu Guo Xi Li Ji-Ye Yin Wei Zheng Xin-Wen Qiu Ling Xiao Rang-Ru Liu Sai-Ying Wang Wei-Jing Gong Hong-Hao Zhou Zhao-Qian Liu |
| author_facet | Di Xiao Yu Guo Xi Li Ji-Ye Yin Wei Zheng Xin-Wen Qiu Ling Xiao Rang-Ru Liu Sai-Ying Wang Wei-Jing Gong Hong-Hao Zhou Zhao-Qian Liu |
| author_sort | Di Xiao |
| collection | DOAJ |
| description | Background. We aimed to investigate the distributive characteristics of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms and their influence on metformin efficacy in Chinese T2DM patients. Methods. The distributions of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms were determined in 267 T2DM patients and 182 healthy subjects. Subsequently, 53 newly diagnosed patients who received metformin monotherapy were recruited to evaluate metformin efficacy. Results. No significant difference was found between T2DM patients and healthy subjects in SLC22A1 rs594709 and SLC47A1 rs2289669 allele frequencies and genotype frequencies. After metformin treatment, SLC22A1 rs594709 GG genotype patients showed a higher increase in FINS (p=0.015) and decrease in HOMA-IS (p=0.001) and QUICKI (p=0.002) than A allele carriers. SLC47A1 rs2289669 GG genotype patients had a higher decrease in TChol (p=0.030) and LDL-C (p=0.049) than A allele carriers. Among SLC22A1 rs594709 AA genotype, patients with SLC47A1 rs2289669 AA genotype showed a higher decrease in FBG (p=0.015), PINS (p=0.041), and HOMA-IR (p=0.014) than G allele carriers. However, among SLC22A1 rs594709 G allele carriers, SLC47A1 rs2289669 AA genotype patients showed a higher decrease in TChol (p=0.013) than G allele carriers. Conclusion. Our data suggest that SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms may influence metformin efficacy together in Chinese T2DM patients. |
| format | Article |
| id | doaj-art-579a96e1fe2e4d13bfe326aae7a46faa |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-579a96e1fe2e4d13bfe326aae7a46faa2025-02-03T06:06:25ZengWileyInternational Journal of Endocrinology1687-83371687-83452016-01-01201610.1155/2016/43507124350712The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes PatientsDi Xiao0Yu Guo1Xi Li2Ji-Ye Yin3Wei Zheng4Xin-Wen Qiu5Ling Xiao6Rang-Ru Liu7Sai-Ying Wang8Wei-Jing Gong9Hong-Hao Zhou10Zhao-Qian Liu11Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaChangsha Medical University Teaching Hospital, The People’s Hospital of Liuyang, Liuyang 410300, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, ChinaBackground. We aimed to investigate the distributive characteristics of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms and their influence on metformin efficacy in Chinese T2DM patients. Methods. The distributions of SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms were determined in 267 T2DM patients and 182 healthy subjects. Subsequently, 53 newly diagnosed patients who received metformin monotherapy were recruited to evaluate metformin efficacy. Results. No significant difference was found between T2DM patients and healthy subjects in SLC22A1 rs594709 and SLC47A1 rs2289669 allele frequencies and genotype frequencies. After metformin treatment, SLC22A1 rs594709 GG genotype patients showed a higher increase in FINS (p=0.015) and decrease in HOMA-IS (p=0.001) and QUICKI (p=0.002) than A allele carriers. SLC47A1 rs2289669 GG genotype patients had a higher decrease in TChol (p=0.030) and LDL-C (p=0.049) than A allele carriers. Among SLC22A1 rs594709 AA genotype, patients with SLC47A1 rs2289669 AA genotype showed a higher decrease in FBG (p=0.015), PINS (p=0.041), and HOMA-IR (p=0.014) than G allele carriers. However, among SLC22A1 rs594709 G allele carriers, SLC47A1 rs2289669 AA genotype patients showed a higher decrease in TChol (p=0.013) than G allele carriers. Conclusion. Our data suggest that SLC22A1 rs594709 and SLC47A1 rs2289669 polymorphisms may influence metformin efficacy together in Chinese T2DM patients.http://dx.doi.org/10.1155/2016/4350712 |
| spellingShingle | Di Xiao Yu Guo Xi Li Ji-Ye Yin Wei Zheng Xin-Wen Qiu Ling Xiao Rang-Ru Liu Sai-Ying Wang Wei-Jing Gong Hong-Hao Zhou Zhao-Qian Liu The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients International Journal of Endocrinology |
| title | The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients |
| title_full | The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients |
| title_fullStr | The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients |
| title_full_unstemmed | The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients |
| title_short | The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients |
| title_sort | impacts of slc22a1 rs594709 and slc47a1 rs2289669 polymorphisms on metformin therapeutic efficacy in chinese type 2 diabetes patients |
| url | http://dx.doi.org/10.1155/2016/4350712 |
| work_keys_str_mv | AT dixiao theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT yuguo theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT xili theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT jiyeyin theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT weizheng theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT xinwenqiu theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT lingxiao theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT rangruliu theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT saiyingwang theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT weijinggong theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT honghaozhou theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT zhaoqianliu theimpactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT dixiao impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT yuguo impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT xili impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT jiyeyin impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT weizheng impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT xinwenqiu impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT lingxiao impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT rangruliu impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT saiyingwang impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT weijinggong impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT honghaozhou impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients AT zhaoqianliu impactsofslc22a1rs594709andslc47a1rs2289669polymorphismsonmetformintherapeuticefficacyinchinesetype2diabetespatients |